LATEST NEWS

Combining a nanoparticle‐mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti‐PD1 resistant lung cancer

For inquiries about our technology, collaborations, clinical trials, or other topics, we encourage you to get in touch with our team.